Listed by the USPTO as ROSENTHAL, ANDREW S
Tech Center 1700 • Art Units: 1612 1613 1615 1624 1715
This examiner grants 52% of resolved cases
ROSENTHAL, ANDREW S works in tech center 1700 and art unit 1612. The profile reports 671 resolved cases, a 51.9% allowance rate, and a median of 1106 days to allowance. The 39.0% interview lift is a strong positive signal and indicates that interviews are associated with improved allowance outcomes.
The listed companies are L'Oréal, Henkel AG & Co. KGaA, and Novartis AG. The listed firms are OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., BakerHostetler, and BOZICEVIC, FIELD & FRANCIS LLP. Applicants should expect substantive prosecution work based on the allowance figure and can give interviews a prominent role when developing a plan to move claims toward allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18802089 | IMMUNOSUPPRESSANT FORMULATIONS | Final Rejection | Novartis AG |
| 18869139 | CONCENTRATED SOLUTIONS COMPRISING SODIUM 5,10-METHYLENE-(6R)-TETRAHYDROFOLATE | Non-Final OA | Merck Patent GMBH |
| 18444413 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING AND USING THE SAME | Non-Final OA | The General Hospital Corporation |
| 17783235 | HAIR STYLING COMPOSITION CONTAINING DISACCHARIDES | Final Rejection | Henkel AG & Co. KGaA |
| 17762674 | METHOD FOR DYEING KERATINOUS MATERIAL BY MEANS OF A PREMIX OF AMINOSILICONE AND A CHROMOPHORIC COMPOUND | Final Rejection | Henkel AG & Co. KGaA |
| 18003744 | CANCER RADIOSENSITIZATION BY IN SITU FORMATION OF GOLD NANOPARTICLES AND/OR GOLD NANOCLUSTERS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18723263 | COSMETIC COMPOSITION COMPRISING A POLYHYDROXYALKANOATE COPOLYMER BEARING A(N) (UN)SATURATED HYDROCARBON-BASED CHAIN AND A NATURAL RESIN | Non-Final OA | L'OREAL |
| 18626294 | COMPOSITIONS AND METHODS FOR ALTERING THE COLOR OF HAIR | Non-Final OA | L'Oreal |
| 15993759 | NON-SULFATE CONCENTRATED RINSE-OFF CLEANSING COMPOSITION | Final Rejection | L'OREAL |
| 18699471 | AGENT FOR PREVENTING, TREATING, OR IMPROVING INFLAMMATORY SKIN DISEASE | Final Rejection | KAO CORPORATION |
| 18357810 | MULTIFUNCTIONAL pO2/pH-SENSITIVE THERANOSTIC LIPOSOME NANOCARRIERS AND METHODS OF USING SAME | Final Rejection | YALE UNIVERSITY |
| 18939930 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | Non-Final OA | NOVONESIS PLANT BIOSOLUTIONS A/S |
| 18265171 | Biliary Delivery Methods, Compositions and Kits for Use Therein | Final Rejection | Cytotheryx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy51.9% of resolved applications examined by Andrew S Rosenthal were allowed (671 resolved cases), compared with 40.7% across Art Unit 1612 over the last five years.
This examiner's interview lift is +39.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Andrew S Rosenthal took 1,106 days on average from filing to allowance.
Andrew S Rosenthal examines applications in Art Unit 1612 in Tech Center 1700 (Chemistry & Materials).
